For research use only. Not for therapeutic Use.
EDP-305（Cat No.:I043467）is a selective, oral agonist of the farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid synthesis, lipid metabolism, and glucose homeostasis. By activating FXR, EDP-305 helps modulate metabolic pathways that are crucial in liver function and overall metabolic health. This compound shows promise in treating liver diseases, such as nonalcoholic steatohepatitis (NASH), where FXR activation may reduce liver inflammation, fibrosis, and fat accumulation. Currently undergoing clinical trials, EDP-305 is being investigated for its potential to improve liver health and manage metabolic disorders.
| CAS Number | 1933507-63-1 |
| Synonyms | 1-(4-tert-butylphenyl)sulfonyl-3-[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl]urea |
| Molecular Formula | C36H58N2O5S |
| Purity | ≥95% |
| IUPAC Name | 1-(4-tert-butylphenyl)sulfonyl-3-[(3R)-3-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl]urea |
| InChI | InChI=1S/C36H58N2O5S/c1-8-26-30-21-24(39)15-18-36(30,7)29-16-19-35(6)27(13-14-28(35)31(29)32(26)40)22(2)17-20-37-33(41)38-44(42,43)25-11-9-23(10-12-25)34(3,4)5/h9-12,22,24,26-32,39-40H,8,13-21H2,1-7H3,(H2,37,38,41)/t22-,24-,26-,27-,28+,29+,30+,31+,32-,35-,36-/m1/s1 |
| InChIKey | SJKLCUGQVVYDCX-HRNVLBFRSA-N |
| SMILES | CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCNC(=O)NS(=O)(=O)C5=CC=C(C=C5)C(C)(C)C)C)C)O |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
